AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12631093
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (benazepril 10 mg/day + valsartan 80 mg/day)
Trial: 12631093
Drug: Combined therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy, Benazepril, Valsartan
Trial: 1353102
Drug: HIVAC-1e vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVAC-1e vaccine
Trial: 31044424
Drug: Noradrenaline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (5 μg)
Trial: 25197807
Drug: Suvorexant 10
RxNorm normalized name: suvorexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 10 mg, 20 mg, 40 mg, 80 mg
Trial: 25197807
Drug: Gaboxadol 15
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol 15 mg, Zolpidem 10 mg, Trazodone 150 mg
Trial: 21868715
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg twice daily on days 1 to 3 and once on day 4
Trial: 21868715
Drug: Digoxin loading
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin loading dose of 0.5 mg on day 1 and 0.25 mg on days 2 to 4
Trial: 17253134
Drug: mesalazine 1.6
RxNorm normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 1.6 g/d (group A)
Trial: 17253134
Drug: mesalazine 1.6
RxNorm normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 1.6 g/d 10 days per month (group B)
Trial: 10965287
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment (Cognitive Therapy or Phenelzine)
Trial: 10965287
Drug: Discontinued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued treatment (Pill placebo)
Trial: 8641739
Drug: Losartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (angiotensin II receptor antagonist)
Trial: 18830043
Drug: Calcitonin (nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (nasal spray preparations)
Trial: 10084441
Drug: Low-dosage pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage pulsed ultrasound (mean dosage 172.8 J)
Trial: 10084441
Drug: High-dosage pulsed
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage pulsed ultrasound (mean dosage 345.6 J)
Trial: 7597425
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks
Trial: 7597425
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2
Trial: 7597425
Drug: Doxorubicin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion
Trial: 1975200
Drug: mequitazine 5
RxNorm normalized name: mequitazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mequitazine 5 mg bd
Trial: 1975200
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg bd
Trial: 24022431
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic treatment followed by delayed laparoscopic cholecystectomy at days 7 to 45 (group DLC)
Trial: 16891381
Drug: Irbesartan (228±93
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (228±93 mg/day) for at least 2 weeks prior to cardioversion
Trial: 12673783
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + NPH insulin at bedtime
Trial: 12673783
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin twice daily
Trial: 12673783
Drug: 30/70 mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/70 mixture of short-acting and NPH insulin twice daily
Trial: 6141727
Drug: Nadolol in
RxNorm normalized name: Product containing nadolol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol in combination with isosorbide dinitrate and nifedipine
Trial: 6141727
Drug: Nadolol and
RxNorm normalized name: nadolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol and large doses of nifedipine
Trial: 6141727
Drug: Nadolol alone
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol alone and in combination with isosorbide dinitrate
Trial: 6141727
Drug: All drug
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drug combinations
Trial: 25536449
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies including screening and treatment of subclinical hypothyroidism
Trial: 23731684
Drug: PEEP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP titration with the four strategies
Trial: 20521648
Drug: Recombinant NDV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant NDV expressing H9 AIV hemagglutinin (HA), administered as a single dose of 10^6 50% egg infectious dose intranasally.
Trial: 12964321
Drug: 12-hour treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Trial: 12964321
Drug: 24-hour treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Trial: 9461709
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with advanced renal insufficiency (serum creatinine levels above 265.3 mumol/l)
Trial: 9461709
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with mild renal failure (serum creatinine levels below 265.3 mumol/l)
Trial: 7948237
Drug: Intraperitoneal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal vancomycin plus oral rifampin
Trial: 7948237
Drug: Oral trimethoprim/sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim/sulfamethoxazole (TMP/SMX)
Trial: 19488999
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus 1-alpha-hydroxyvitamin D3 (1-alpha(OH)D3; 0.5 microg per day)
Trial: 16688412
Drug: Almotriptan (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (6.25 to 12.5 mg)
Trial: 15305946
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (Triamcinolone, Montelukast, Nedocromil)
Trial: 8217174
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose and lactated Ringer's solution
Trial: 8217174
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusions
Trial: 31577797
Drug: Group antenatal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group antenatal care (G-ANC)
Trial: 31368121
Drug: Single implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single implant mandibular overdenture (SIO)
Trial: 24827469
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (twice weekly for 6 weeks)
Trial: 16003267
Drug: Preload reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preload reduction with Valsalva maneuver (nonstandardized and standardized) and sublingual nitroglycerin
Trial: 12033698
Drug: Twelve-Step Facilitation
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve-Step Facilitation (TSF) therapy
Trial: 12033698
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET)
Trial: 7564453
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (10 gm intravenously over 20 minutes before sternotomy and a placebo infusion over 5 hours)
Trial: 7564453
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (10 gm intravenously over 20 minutes and another 10 gm infused over 5 hours)
Trial: 7564453
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline solution bolus and infusion over 5 hours)
Trial: 7564453
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (10 gm)
Trial: 7564453
Drug: Continued tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued tranexamic acid infusion (10 gm over 5 hours)
Trial: 2075481
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg (regimen A)
Trial: 2075481
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg (regimen B)
Trial: 6992823
Drug: Labetalol (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400-800 mg daily)
Trial: 6992823
Drug: Labetalol (1200-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (1200-1600 mg daily)
Trial: 6992823
Drug: Acebutolol (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400-800 mg daily)
Trial: 27662018
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (4 cycles of standard anthracycline-based chemotherapy)
Trial: 27662018
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction chemotherapy
Trial: 27662018
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (per protocol)
Trial: 27662018
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction chemotherapy (per protocol)
Trial: 27662018
Drug: MEL140 (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL140 (high-dose melphalan)
Trial: 27662018
Drug: Mobilization chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization chemotherapy and tandem MEL140
Trial: 22248762
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL to 0.5% ropivacaine
Trial: 22248762
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL to 0.5% ropivacaine
Trial: 22248762
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL to 1% ropivacaine
Trial: 17118993
Drug: Counterregulatory hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counterregulatory hormones during exercise
Trial: 11916896
Drug: Daily micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily micronutrient enriched foods (25‐100% recommended daily amount)
Trial: 9859596
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available tablet (control)
Trial: 7889183
Drug: Oral TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRH (40 mg, 12 hourly) plus metoclopramide (10 mg, 8 hourly)
Trial: 7889183
Drug: Oral TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRH (40 mg, 12 hourly) plus placebo (one capsule, 8 hourly)
Trial: 27574260
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.375% ropivacaine plus tramadol 50 mg
Trial: 27574260
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.375% ropivacaine plus tramadol 100 mg
Trial: 22949150
Drug: Gemcitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,250 mg/m² days 1 and 8 of a 3-week cycle)
Trial: 22949150
Drug: Second-line pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line pemetrexed (500 mg/m² once every 21 days)
Trial: 17604912
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg cortisol (oral administration)
Trial: 16100331
Drug: Culturally competent
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally competent dietary self‐management intervention consisting of 4 weekly classes in low‐fat dietary strategies, 5 monthly peer‐professional group discussions, and weekly telephone follow‐up
Trial: 12859585
Drug: Oral eletriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eletriptan 40 mg
Trial: 15679698
Drug: Oral eletriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eletriptan 80 mg
Trial: 10370679
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Ceftriaxone
Trial: 10370679
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g Ceftriaxone
Trial: 10370679
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g or 2 g)
Trial: 8958612
Drug: Warfarin (Coumadin)
RxNorm normalized name: WARFARIN (COUMADIN) NA 1MG TAB
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (Coumadin) therapy with guidelines for initiation, monitoring, and reversal
Trial: 1515384
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml physiologic saline
Trial: 1515384
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml (1 mg) 0.5% phenylephrine plus 0.8 ml normal saline
Trial: 1515384
Drug: 0.4 ml
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml phenylephrine plus 0.6 ml normal saline
Trial: 1515384
Drug: 0.6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 ml phenylephrine plus 0.4 ml normal saline
Trial: 1515384
Drug: 0.8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml phenylephrine plus 0.2 ml normal saline
Trial: 6093522
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g daily
Trial: 6093522
Drug: Cefazolin 3
RxNorm normalized name: cefazolin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 3 to 4 g daily
Trial: 30449536
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone at 10 mg
Trial: 30449536
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate at 160 mg
Trial: 25929594
Drug: Eltrombopag 25
RxNorm normalized name: eltrombopag 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 25 mg once daily
Trial: 25526812
Drug: Multi-dimensional family
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dimensional family therapy (MDFT)
Trial: 12566370
Drug: Enalaprilat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (5 micro g/min)
Trial: 12566370
Drug: Enalaprilat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (5 micro g/min) with bradykinin (100 ng/min)
Trial: 7972348
Drug: Propentofylline at
RxNorm normalized name: propentofylline
DrugBank: Propentofylline (DB06479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propentofylline at 0.9 g/d
Trial: 2890150
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg at night)
Trial: 2570005
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg at night)
Trial: 16801
Drug: triazolam 0-5
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triazolam 0-5 mg
Trial: 16801
Drug: triazolam 0-25
RxNorm normalized name: triazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triazolam 0-25 mg
Trial: 19629539
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic treatment and standard care (Control group)
Trial: 15142023
Drug: Creatine powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine powder in solution (CP) - 20 g.day(‐1) x 6 days
Trial: 15142023
Drug: Creatine serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine serum (CS) - 5 ml.day(‐1) x 6 days
Trial: 11701194
Drug: 4 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 standard units of alcohol (40 g) under fasting conditions
Trial: 11701194
Drug: 4 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 standard units of alcohol (40 g) after food consumption
Trial: 365544
Drug: Timolol and
RxNorm normalized name: timolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol and bendrofluazide (once daily dosage)
Trial: 365544
Drug: Timolol and
RxNorm normalized name: timolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol and bendrofluazide (twice daily dosage)
Trial: 28093841
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg daily)
Trial: 23500262
Drug: Rivaroxaban (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (both doses)
Trial: 19318434
Drug: Homozygous for
RxNorm normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homozygous for the G allele of the PRKDC rs7003908 variant
Trial: 8959084
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (20 mg) administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Trial: 8959084
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Trial: 3893730
Drug: Naproxen (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (initial dose 750 mg, additional 250-500 mg as needed, max 5 tablets in 24h)
Trial: 31610549
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg/d or 15 mg/d, according to renal function)
Trial: 31610549
Drug: Dose‐adjusted vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐adjusted vitamin K antagonists (VKAs)
Trial: 27321312
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + DPP4 inhibitors
Trial: 27321312
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + insulin-secretagogues (IS)
Trial: 22128201
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) with standard breakfast
Trial: 22128201
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) in fasted state
Trial: 12494713
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) using glass-ionomer (GI) and compomer materials
Trial: 12494713
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention treatment (MIT) using glass-ionomer (GI) and compomer materials
Trial: 2533042
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg twice daily for 19 patients, 10 mg twice daily for 2 patients)
Trial: 31813636
Drug: Accelerated Partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Partial Breast Irradiation (APBI) delivered as 34 Gy of brachytherapy or 38.5 Gy of external beam radiation therapy in 10 fractions over 5 treatment days within an 8-day period.
Trial: 31813636
Drug: Whole-breast irradiation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-breast irradiation delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed.